Trial of Lantigen B for prevention of thrombo-embolic accidents Study session on thrombo-embolic disease, Paris-UNESCO, 15 December, 1963

Lauras, H.; Robert, C.; Roux, C.; Simon, E.

ANN ANESTH FRANC 5(Spec no ): 157-158

1964


Accession: 026014702

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Lantigen B is a microbial lysate of Pneumococcus types I, II, III, V, and VIE, streptococci, Neisseriacatarrhalis, Staphylococcus "doreey," Klebsiella pneumoniae, and Hemophilus influenzae. When given 10-12 hours pre-operatively to 350 patients, 7 showed a slight malleolar edema from phlebothrombosis; in 400 control patients not receiving Lantigen B, there were 18 cases of phlegmasia alba dolens with edema, 4 pulmonary emboli and 2 deaths. Except in emergency surgery, Lantigen should be given orally, routinely.